Evidence map›Paper›PMID 40940133›Full record

ArticleJournal for immunotherapy of cancer2025

Genome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity.

Xiaoling Tian, Guolong Liu, Qiudao Wang, Na Zhang, Yanting Shen, Bing Du, Yuxuan Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. KMT5a-Mediated IRF3 Stabilization Enhances Macrophage Chemotaxis and Renal Fibrosis Progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoling Tian *East China Normal University, Shanghai, China.ORCID http://orcid.org/0009-0006-7967-2855
Guolong Liu *East China Normal University, Shanghai, China.ORCID http://orcid.org/0009-0002-1477-1589
Qiudao WangEast China Normal University, Shanghai, China.ORCID http://orcid.org/0009-0000-9687-0331
Na ZhangBRL Medicine, Inc, Shanghai, China.ORCID http://orcid.org/0000-0003-4346-2910
Yanting ShenEast China Normal University, Shanghai, China.
Bing DuEast China Normal University, Shanghai, China yxwu@bio.ecnu.edu.cn bdu@bio.ecnu.edu.cn.ORCID http://orcid.org/0000-0002-5402-6527
Yuxuan WuEast China Normal University, Shanghai, China yxwu@bio.ecnu.edu.cn bdu@bio.ecnu.edu.cn.ORCID http://orcid.org/0000-0002-9155-9883

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdoptive T-cell therapy has emerged as a promising therapeutic strategy for cancer treatment. However, clinical challenges persist, including the limited ability of CD8+T cells to infiltrate solid tumors and efficiently eliminate tumor cells. Given the critical role of epigenetic mechanisms in antitumor immunity, targeting epigenetic regulators represents a critical step toward optimizing adoptive T-cell therapies for solid tumors.

methodsTo investigate the role of

resultsWe report that lysine methyltransferase

conclusionsOur findings establish

Indexed as

CD8-Positive T-LymphocytesGene EditingHistone-Lysine N-MethyltransferaseImmunotherapy, AdoptiveReceptors, Chimeric AntigenAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysHistone-Lysine N-MethyltransferaseReceptors, Chimeric AntigenAdoptive cell therapy - ACT

Identifiers

PMID40940133
PMCPMC12519333

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.